Expert Opinion on Drug Safety

Titel Veröffentlichungsdatum Sprache Zitate
Safety of current treatment options for NTRK fusion-positive cancers2023/10/31English
Interstitial lung disease and CDK4/6 inhibitors in the treatment of breast cancer2023/11/26English
Analysis of drug-induced posterior reversible encephalopathy syndrome using the food and drug administration adverse drug events reporting system database2024/03/13English
Data mining and safety analysis of traditional immunosuppressive drugs: a pharmacovigilance investigation based on the FAERS database2024/03/27English
Hemorrhage induced by antithrombotic agents: new insights from a real-world pharmacovigilance study2024/03/18English
A comprehensive analysis of liver safety across zibotentan oncology trials: knowledge of the past offers new perspectives on the present2024/03/24English
Dupilumab in real-life settings: a review of adverse events and their pathogenesis2024/03/12English
Tolerability and safety outcomes of first-line oral second-generation antipsychotics in patients with schizophrenia2024/03/25English
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: what do we know and future vistas2024/03/26English
A real-world pharmacovigilance study of QT interval prolongation and Torsades de Pointes associated with CDK4/6 inhibitors in breast cancer patients: findings from the FDA adverse event reporting system2024/03/14English
Liver toxicity in oncology trials and beyond: a simplified concept for management of hepatocellular drug-induced liver injury in patients with abnormal baseline liver tests2024/04/02English
A safety review of tyrosine kinase inhibitors for chronic myeloid leukemia2024/04/01English
Identification of adverse drug reactions that may be related to pharmacogenetics in a public hospital in the South of Brazil2023/02/26English
Application of tree-based machine learning classification methods to detect signals of fluoroquinolones using the Korea Adverse Event Reporting System (KAERS) database2023/02/23English
Sex differences in adverse drug reactions from Adalimumab and etanercept in patients with inflammatory rheumatic diseases2023/03/01English
Safety and effectiveness of rivaroxaban for prevention of stroke in patients with nonvalvular atrial fibrillation: analysis of routine clinical data from four countries2023/02/22English
Potential drug-drug interactions in adults receiving oral anticoagulant and antiaggregant therapy2023/03/01English
Contributory factors and patient harm including deaths associated direct acting oral anticoagulants (DOACs) medication incidents: evaluation of real world data reported to the National Reporting and Learning System2023/06/18English
Safety and efficacy of personalized versus standard initial dosing of thiopurines: Systematic review and meta-analysis of randomized trials2023/07/18English
Will the future of pharmacovigilance be more automated?2023/07/03English
Post-Marketing Safety Concerns with Upadacitinib: A Disproportionality Analysis of the FDA Adverse Event Reporting system2023/06/20English
Immune checkpoint inhibitor related myositis: an observational, retrospective, pharmacovigilance study2024/04/24English
Incidence and risk factors for potential drug-drug interactions in outpatients receiving opioid analgesics2024/04/23English
Efficacy and safety of bimekizumab in the treatment of psoriatic arthritis: a systematic review and meta-analysis2024/04/23English
Comprehensive safety profile of dipeptidyl peptidase-4 inhibitors: a post-marketing study based on FAERS database using signal detection algorithms2024/04/23English
Comparative effectiveness and safety of drug therapy for chronic urticaria: a network meta-analysis and risk-benefit assessment2023/09/25English
A systematic review and meta-analysis of the prevalence and association between levonorgestrel and ectopic pregnancy2023/08/17English
A real-world disproportionality analysis of ospemifene: data mining of the public version of FDA adverse event reporting system2023/08/24English
Severe cutaneous adverse reactions associated with immune checkpoint inhibitors therapy and anti-VEGF combination therapy: a real-world study of the FDA adverse event reporting system2023/08/25English
Comparing adverse events of tenecteplase and alteplase: a real-world analysis of the FDA adverse event reporting system (FAERS)2023/08/18English